In the aftermath of the COVID-19 pandemic, biotech investment, previously described as entering a “nuclear winter,” has rebounded, marking three consecutive quarters of heightened activity. This resurgence emphasizes a shift in focus: investments are now flowing towards high-value assets that address unmet needs and demonstrate rapid value, as both investors and regulators prioritize a clear and integrated value narrative. Companies that fail to adapt their development plans to reflect this new environment risk misalignment with regulatory expectations, which could lead to increased costs and operational delays. Ultimately, the current landscape rewards those who build robust evidence and strategic approaches rather than rushing to capitalize on available funding.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pharmaphorum.com/market-access/biotech-funding-has-returned-bar-has-moved-it
